Keymed Biosciences Inc. (HKG:2162)
Hong Kong
· Delayed Price · Currency is HKD 48.00
-0.10 (-0.21%)
Apr 3, 2025, 4:08 PM HKT
Keymed Biosciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 428.12 | 354.1 | 100.06 | 110.27 | - | Upgrade
|
| Revenue Growth (YoY) | 20.91% | 253.87% | -9.26% | - | - | Upgrade
|
| Cost of Revenue | 12.2 | 36.88 | 2.59 | 17.2 | - | Upgrade
|
| Gross Profit | 415.92 | 317.22 | 97.48 | 93.07 | - | Upgrade
|
| Selling, General & Admin | 298.83 | 177.01 | 133.91 | 92.45 | 21.55 | Upgrade
|
| Research & Development | 735.19 | 596.28 | 507.37 | 358.16 | 127.4 | Upgrade
|
| Other Operating Expenses | 7.99 | 1.36 | 0.68 | 2.96 | 0.03 | Upgrade
|
| Operating Expenses | 1,042 | 774.65 | 641.97 | 453.57 | 148.98 | Upgrade
|
| Operating Income | -626.09 | -457.43 | -544.49 | -360.5 | -148.98 | Upgrade
|
| Interest Expense | -18.46 | -17.26 | -8.4 | -11.13 | -14.31 | Upgrade
|
| Interest & Investment Income | 88.33 | 88.35 | 54.32 | 7.01 | 5.48 | Upgrade
|
| Earnings From Equity Investments | -5.26 | -4.75 | -9.71 | -0.72 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 18.15 | 11.08 | 139.03 | -54.72 | 21.78 | Upgrade
|
| Other Non Operating Income (Expenses) | 34.68 | 23.82 | 65.66 | -13.78 | 13.48 | Upgrade
|
| EBT Excluding Unusual Items | -508.65 | -356.19 | -303.6 | -433.84 | -122.54 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.16 | Upgrade
|
| Other Unusual Items | - | - | - | -3,459 | -696.47 | Upgrade
|
| Pretax Income | -508.65 | -356.19 | -303.6 | -3,893 | -818.85 | Upgrade
|
| Income Tax Expense | 6.26 | 1.6 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -514.91 | -357.79 | -303.6 | -3,893 | -818.85 | Upgrade
|
| Minority Interest in Earnings | -0.33 | -1.57 | -4.52 | 5.32 | 0.27 | Upgrade
|
| Net Income | -515.24 | -359.36 | -308.12 | -3,887 | -818.58 | Upgrade
|
| Net Income to Common | -515.24 | -359.36 | -308.12 | -3,887 | -818.58 | Upgrade
|
| Shares Outstanding (Basic) | 262 | 261 | 261 | 161 | 67 | Upgrade
|
| Shares Outstanding (Diluted) | 262 | 261 | 261 | 161 | 67 | Upgrade
|
| Shares Change (YoY) | 0.22% | 0.09% | 62.34% | 139.72% | - | Upgrade
|
| EPS (Basic) | -1.97 | -1.37 | -1.18 | -24.17 | -12.20 | Upgrade
|
| EPS (Diluted) | -1.97 | -1.37 | -1.18 | -24.17 | -12.20 | Upgrade
|
| Free Cash Flow | - | -630.81 | -680.76 | -386.42 | -139.17 | Upgrade
|
| Free Cash Flow Per Share | - | -2.41 | -2.61 | -2.40 | -2.07 | Upgrade
|
| Gross Margin | 97.15% | 89.59% | 97.42% | 84.40% | - | Upgrade
|
| Operating Margin | -146.24% | -129.18% | -544.15% | -326.93% | - | Upgrade
|
| Profit Margin | -120.35% | -101.49% | -307.92% | -3525.30% | - | Upgrade
|
| Free Cash Flow Margin | - | -178.15% | -680.33% | -350.44% | - | Upgrade
|
| EBITDA | -574.46 | -405.8 | -522.22 | -347.7 | -135.09 | Upgrade
|
| EBITDA Margin | -134.18% | -114.60% | - | - | - | Upgrade
|
| D&A For EBITDA | 51.63 | 51.63 | 22.27 | 12.8 | 13.89 | Upgrade
|
| EBIT | -626.09 | -457.43 | -544.49 | -360.5 | -148.98 | Upgrade
|
| EBIT Margin | -146.24% | -129.18% | - | - | - | Upgrade
|
Updated Sep 23, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.